SOURCE: HealthSonix, Inc.

September 06, 2007 10:50 ET

HealthSonix Business Developments on Target

IRVINE, CA--(Marketwire - September 6, 2007) - HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) today released the following statement from Dieter Doederlein, Vice President, Corporate Development at HealthSonix.

"Due to the many contacts that we have received from shareholders and new investors requesting updates on the various initiatives that were announced during the summer, we are pleased to provide the following summary of the stages where those initiatives presently are, and when we expect completion:

    1.  The infomercial for the enSonix@home unit is in final production
        stage: the production company is doing some last minute additional
        'in the field' shooting before the final edits are done. Revised
        air time is early October;

    2.  The enSonix@home device is undergoing QC testing for efficacy,
        overall performance and durability. Sign offs to start the
        manufacturing are expected within 30 days.

    3.  The in the field joint marketing program with a pharmaceutical
        company is scheduled to commence mid September, at which time the
        name of the company will be in the public domain;

    4.  HealthSonix plans to apply for a listing on the AMEX before the
        end of this calendar year; all the necessary documentation to be
        filed with the regulators is being prepared towards that end.

    5.  Management has scheduled IR meetings in New York, starting
        September 18th, right through the end of November to acquaint
        institutions and retail brokerage houses with the HealthSonix
        products and services;

    6.  The ZingiberRx sampling program continues to yield good results:
        retail listing is underway in a test market using local newspapers
        to distribute coupons directing the audience to pharmacies.

"We are moving forward on many different fronts and the positive feedback and the encouragement that we have received from our partners and patients serve to confirm that we are on the right track. We are looking forward with much anticipation to an exciting fall and winter," said Doederlein.

HealthSonix, Inc. (PINKSHEETS: HSXI) (FRANKFURT: H7S) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All treatments and products are safe, non-invasive, and have no known side effects.

More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.

Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.

Contact Information